Precision BioSciences announces new and late-breaking PBGENE-HBV clinical data from the ELIMINATE-B study at european association for the Study of the Liver Congress 2026
[출처/시간] Briefing.com - 6:01 AM ET, 05/27/2026 New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts.In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function.gRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -New clinical data
뉴스|admin|May 27, 2026
[출처/시간] Briefing.com - 6:01 AM ET, 05/27/2026
New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts.In the <1% of cccDNA remaining, PBGENE-HBV indels permanently inactivated viral replication by knocking out polymerase function.gRNA established as the biomarker to directly reflect cccDNA elimination by PBGENE-HBV -New clinical data demonstrate that PGENE-HBV achieved pgRNA loss in 100% of patients with detectable pgRNA at baseline -PBGENE-HBV has a clear therapeutic window with a well-characterized and manageable safety profile across multiple dosing cohorts -
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.